Gary D Kukes

Learn More
Nonalcoholic fatty liver disease (NAFLD), a leading cause of liver damage, comprises a spectrum of liver abnormalities including the early fat deposition in the liver (hepatic steatosis) and advanced nonalcoholic steatohepatitis. Niacin decreases plasma triglycerides, but its effect on hepatic steatosis is elusive. To examine the effect of niacin on(More)
Transforming growth factor-beta1 (TGF-beta1) is a growth factor that is implicated in fibrosis of many organs. The purpose of this study was to determine the sequential levels of TGF-beta1 in the pleural fluid of rabbits that had undergone empyema induction, as fibrosis of the pleural space develops. Thirty-seven rabbits underwent empyema induction. Rabbits(More)
STUDY OBJECTIVES Transforming growth factor (TGF)-beta is a cytokine that has been demonstrated to be an important modulator of inflammation and angiogenesis, as well as a potent stimulator of pleural fluid production and fibrosis. We previously demonstrated that rising levels of pleural fluid TGF-beta(1) correlate with pleural fibrosis in experimental(More)
Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenic disorder with progressive distension of multiple tubular segments, and is manifested by fluid accumulation, growth of epithelial cells, and remodeling of the extracellular matrix, ultimately resulting in renal insufficiency in one half of affected individuals. The process causing the(More)
Intracellular ionic concentrations, membrane potential and Na+ and K+ flux were measured in a clonal rat glial cell line, C6. Intracellular concentrations of C6 cells were: (mmole/liter cell water) K+ 145 +/- 4 S.D., Na+ 18 +/- 4 S.D., Cl- 14 +/- 1 S.D. Cells maintained a steady state level of K+ over the duration of the experiments. This was substantiated(More)
The Felodipine Atherosclerosis Prevention Study is designed to evaluate the efficacy of the calcium antagonist felodipine ER and combined felodipine/simvastatin therapy on retarding the progression of atherosclerosis, estimated by serial changes in coronary calcium evaluated by noninvasive electron beam computed tomography. Subjects include 180 men and(More)
We have produced a monoclonal antibody CCOL1 that is cytotoxic at a titer of 1:20,000 using human sera as a complement source. CCOL1 reacts to the immunizing colon carcinoma line as well as to one other colon carcinoma line. However, it does not react with another colon adenocarcinoma line or with 28 other cultured tumor cells. It is noncytotoxic to(More)
A monoclonal antibody, CSTO-1, has been produced against a stomach adenocarcinoma-associated antigen. The antibody is cytotoxic to stomach, colon, and lung adenocarcinoma lines but is completely noncytotoxic to normal blood elements and leukemic cell lines. The monoclonal antibody reacts with tumor cell membranes in enzyme-linked immunosorbent assay and is(More)